COMMUNIQUÉS West-GlobeNewswire

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
28/07/2024
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers ( [...]
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
27/07/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Second Quarter 2024 Financial Results on August 1, 2024
26/07/2024
FREDERICK, Md., July 26, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
26/07/2024
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an [...]
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
26/07/2024
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, [...]
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
26/07/2024
Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company [...]
EssilorLuxottica: Publication of the 2024 Interim Financial Report
26/07/2024
Publication of the 2024 Interim Financial Report Paris, France (July 26, 2024 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial [...]
EssilorLuxottica: Mise à disposition du Rapport financier semestriel 2024
26/07/2024
Mise à disposition du Rapport financier semestriel 2024 Paris, France (26 juillet 2024 – 18h30) – Le Conseil d’administration d’EssilorLuxottica, qui s’est réuni le 25 juillet 2024, a arrêté les comptes consolidés [...]
eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
26/07/2024
BOSTON, July 26, 2024 (GLOBE NEWSWIRE) -- eLabNext, a leading provider of digital lab management solutions, and ABI-LAB , a premier life sciences incubator located in Natick, MA, have announced a strategic alliance [...]
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
26/07/2024
July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro [...]
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
26/07/2024
SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
26/07/2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
26/07/2024
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology [...]
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26/07/2024
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its [...]
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
26/07/2024
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) [...]
OneMedNet Announces $4.6 Million Private Placement
26/07/2024
Institutional investors include affiliates of Off the Chain Capital and Discovery Capital Management MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), [...]
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26/07/2024
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 [...]
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26/07/2024
Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical [...]
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
26/07/2024
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1 ,2,3,4 In the [...]

Pages